These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 36803869)

  • 41. Multiple independent emergences of type 2 vaccine-derived polioviruses during a large outbreak in northern Nigeria.
    Burns CC; Shaw J; Jorba J; Bukbuk D; Adu F; Gumede N; Pate MA; Abanida EA; Gasasira A; Iber J; Chen Q; Vincent A; Chenoweth P; Henderson E; Wannemuehler K; Naeem A; Umami RN; Nishimura Y; Shimizu H; Baba M; Adeniji A; Williams AJ; Kilpatrick DR; Oberste MS; Wassilak SG; Tomori O; Pallansch MA; Kew O
    J Virol; 2013 May; 87(9):4907-22. PubMed ID: 23408630
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Update on Vaccine-Derived Polioviruses - Worldwide, January 2014-March 2015.
    Diop OM; Burns CC; Sutter RW; Wassilak SG; Kew OM;
    MMWR Morb Mortal Wkly Rep; 2015 Jun; 64(23):640-6. PubMed ID: 26086635
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Outbreak of poliomyelitis--Angola, 1999.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 1999 Apr; 48(16):327-9. PubMed ID: 10366140
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Implementing a robust adverse event of special interest surveillance for novel oral polio vaccine type 2 rollout, Nigeria, March-July 2021.
    Abbott SL; Etapelong SG; Gidado S; Mawashi KY; Edukugho AA; Hamisu AW; Shehu A; Adedire E; Hassan IA; Waziri NE; Bolu O; Adamu US
    Pan Afr Med J; 2023; 45(Suppl 2):6. PubMed ID: 38370101
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The impact of disruptions caused by the COVID-19 pandemic on global polio eradication.
    Kalkowska DA; Voorman A; Pallansch MA; Wassilak SGF; Cochi SL; Badizadegan K; Thompson KM
    Vaccine; 2023 Apr; 41 Suppl 1():A12-A18. PubMed ID: 33962838
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Emergence of vaccine-derived poliovirus type 2 after using monovalent type 2 oral poliovirus vaccine in an outbreak response, Philippines.
    Alipon SB; Takashima Y; Avagyan T; Grabovac V; Aslam SK; Bayutas B; Logronio J; Wang X; Shrestha A; Neupane S; Roces MC; Apostol LN; Sucaldito N
    Western Pac Surveill Response J; 2022; 13(2):1-7. PubMed ID: 36276175
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Real-time prediction model of cVDPV2 outbreaks to aid outbreak response vaccination strategies.
    Voorman A; O'Reilly K; Lyons H; Goel AK; Touray K; Okiror S
    Vaccine; 2023 Apr; 41 Suppl 1(Suppl 1):A105-A112. PubMed ID: 34483024
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Global oral poliovirus vaccine stockpile management as an essential preparedness and response mechanism for type 2 poliovirus outbreaks following global oral poliovirus vaccine type 2 withdrawal.
    Harutyunyan V; Quddus A; Pallansch M; Zipursky S; Woods D; Ottosen A; Vertefeuille J; Lewis I
    Vaccine; 2023 Apr; 41 Suppl 1(Suppl 1):A70-A78. PubMed ID: 35282924
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Threat of resurgence or hope for global eradication of poliovirus?
    Kim CY; Piamonte B; Allen R; Thakur KT
    Curr Opin Neurol; 2023 Jun; 36(3):229-237. PubMed ID: 37078665
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Genetic Characterization of Novel Oral Polio Vaccine Type 2 Viruses During Initial Use Phase Under Emergency Use Listing - Worldwide, March-October 2021.
    Martin J; Burns CC; Jorba J; Shulman LM; Macadam A; Klapsa D; Majumdar M; Bullows J; Frolov A; Mate R; Bujaki E; Castro CJ; Bullard K; Konz J; Hawes K; Gauld J; Blake IM; Mercer LD; Kurji F; Voorman A; Diop OM; Oberste MS; Modlin J; Macklin G; Eisenhawer M; Bandyopadhyay AS; Zipursky S
    MMWR Morb Mortal Wkly Rep; 2022 Jun; 71(24):786-790. PubMed ID: 35709073
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Exploring public perceptions of vaccine-derived poliovirus and a novel oral polio vaccine in the Democratic Republic of the Congo, Kenya, and Nigeria.
    Lorenzetti L; Haydarov R; Namey E; Lawton A; Nam H; Ridwan Hasan M; Monj C; Abeyesekera S; Amina Kabwau M; McIntosh R
    Vaccine; 2023 Apr; 41 Suppl 1():A128-A135. PubMed ID: 35871107
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Virologic Monitoring of Poliovirus Type 2 after Oral Poliovirus Vaccine Type 2 Withdrawal in April 2016 - Worldwide, 2016-2017.
    Diop OM; Asghar H; Gavrilin E; Moeletsi NG; Benito GR; Paladin F; Pattamadilok S; Zhang Y; Goel A; Quddus A
    MMWR Morb Mortal Wkly Rep; 2017 May; 66(20):538-542. PubMed ID: 28542124
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Responding to a cVDPV1 outbreak in Ukraine: Implications, challenges and opportunities.
    Khetsuriani N; Perehinets I; Nitzan D; Popovic D; Moran T; Allahverdiyeva V; Huseynov S; Gavrilin E; Slobodianyk L; Izhyk O; Sukhodolska A; Hegazi S; Bulavinova K; Platov S; O'Connor P
    Vaccine; 2017 Aug; 35(36):4769-4776. PubMed ID: 28528761
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Progress toward poliomyelitis eradication--Angola and the Democratic Republic of Congo, January 2002-June 2003.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2003 Aug; 52(34):816-9. PubMed ID: 12944879
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Progress Toward Poliomyelitis Eradication - Pakistan, January 2020-July 2021.
    Mbaeyi C; Baig S; Khan Z; Young H; Kader M; Jorba J; Safdar MR; Jafari H; Franka R
    MMWR Morb Mortal Wkly Rep; 2021 Oct; 70(39):1359-1364. PubMed ID: 34591827
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Interrupting wild poliovirus transmission using oral poliovirus vaccine: environmental surveillance in high-risks area of India.
    Chowdhary R; Dhole TN
    J Med Virol; 2008 Aug; 80(8):1477-88. PubMed ID: 18551602
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Analysis of a Sabin-Strain Inactivated Poliovirus Vaccine Response to a Circulating Type 2 Vaccine-Derived Poliovirus Event in Sichuan Province, China 2019-2021.
    Yang H; Qi Q; Zhang Y; Wen N; Cao L; Liu Y; Fan C; Yan D; Zhu X; Hao L; Zhu S; Ma Q; Liu J; Ma C; Nan L; Chen Y; Ma X; Chen N; Deng K; Shao G; Ding X; An Z; Rodewald LE; Li X; Wang D; Zhu H; Wang H; Feng Z; Xu W; Zhou J; Yin Z;
    JAMA Netw Open; 2023 Jan; 6(1):e2249710. PubMed ID: 36602797
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Response to back-to-back outbreaks of circulating vaccine-derived poliovirus type 2 in two nomadic pastoralist settlements in Oti Region, Ghana-2019.
    Ameme DK; Yeboah YO; Odoom JK; Djokoto SK; Akyereko E; Mamudu A; Diwura M; Opare W; Avevor P; Diamenu S; Ohene SA; Kenu E; Asiedu-Bekoe F
    Arch Public Health; 2023 Jan; 81(1):1. PubMed ID: 36600260
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cessation of Trivalent Oral Poliovirus Vaccine and Introduction of Inactivated Poliovirus Vaccine - Worldwide, 2016.
    Hampton LM; Farrell M; Ramirez-Gonzalez A; Menning L; Shendale S; Lewis I; Rubin J; Garon J; Harris J; Hyde T; Wassilak S; Patel M; Nandy R; Chang-Blanc D;
    MMWR Morb Mortal Wkly Rep; 2016 Sep; 65(35):934-8. PubMed ID: 27606675
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Poliomyelitis in Angola: current status and implications for poliovirus eradication in Southern Africa.
    Izurieta HS; Biellik RJ; Kew OM; Valente FL; Chezzi C; Sutter RW
    J Infect Dis; 1997 Feb; 175 Suppl 1():S24-9. PubMed ID: 9203688
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.